Profilequant WT1 kit gets CE marking
Ipsogen has announced the CE marking of its Profilequant WT1 kit.
The WT1 (for Wilms' tumour gene) biomarker is used in the prognosis and follow-up of normal karyotype AML patients, who account for nearly half of AML adult patients.
Quantification of WT1 expression level helps predict disease aggressiveness and determine patient response to treatment.
In a recent European study, WT1 proved to be a reliable indicator that can be used for minimal residual disease monitoring distinguishing patients at differing risk of relapse.
The WT1 assay has been developed in the context of a collaborative project coordinated by the ELN consortium, systematically evaluating nine different available assays to identify the best performing one.
'The WT1 gene has been reported to be switched on in the majority of cases of AML making it an attractive target for novel treatment approaches and monitoring response to therapy,' said David Grimwade, leader of the minimal residual disease working group of ELN.
'Therefore, there was a pressing need to develop a highly reproducible and reliable assay that quantifies WT1 transcript levels,' he added.
The CE marking obtained by Ipsogen for the Profilequant WT1 kit confirms the quality of its validation and manufacturing processes.
With this kit, Ipsogen continues to contribute to the standardisation efforts in place in Europe to reduce inter-laboratory variability and provide consistent results over time.
Ipsogen, a molecular diagnostic company specialising in diagnostic assays for breast cancer and leukaemia, has announced the European launch of the Mapquant Dx HR test.
Ipsogen has announced that Helene Peyro-Saint-Paul has joined the company as chief medical officer.
Ipsogen, a cancer profiler that markets molecular diagnostic assays for leukemia and breast cancer, has announced the European launch of Mapquant DX Her2 test.
Ipsogen has introduced the Mapquant Dx HER2 test which determines tumour HER2 status and guides Herceptin prescription for breast cancer.
Ipsogen has announced a non-exclusive license agreement with Quest Diagnostics for the use of the Jak2 V617F mutation in Quest Diagnostics's laboratory developed tests.